Pei-bo Li

Dr. Pei-bo Li


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Molecules
Verified
Journal Article
Open access
PDF file
ZHZhi-Qiang Huang
Zhi-Qiang Huang
CPChen Pan
Chen Pan
WSWeiwei Su
Weiwei Su
YWYonggang Wang
Yonggang Wang
HWHao Wu
Hao Wu
PLPei-bo Li
Pei-bo Li
Hypericum japonicum is traditionally used as a folk medicine to treat cholestasis and hepatitis. Quercetin 7-rhamnoside (Q7R) is one of the main flavonoid components of Hypericum japonicum and has been rarely studied. The aim of the present study was to evaluate the antioxidant activity and hepatoprotective potential of Q7R. In the in vitro experiments, DPPH, ABTS and ferric reducing antioxidant power (FRAP) assays were first performed to assess the antioxidant properties of Q7R, and then a H2O2-induced oxidative damage cellular model was used to determine the cytoprotective and antioxidant properties of Q7R in human liver L-02 cells. In the in vivo experiment, the hepatoprotective activity of Q7R was evaluated by carbon tetrachloride (CCl4)-induced liver damage model in mice. The results of the three in vitro assays (DPPH, ABTS and FRAP) demonstrated that Q7R significantly exhibited antioxidant activity. The cell experiment results showed that Q7R possessed cytoprotective and antioxidant effects on H2O2-treated L-02 cells. In the in vivo experiments, Q7R suppressed the up-regulation of serum activities of ALT, AST, LDH and triglyceride (TG) levels with dose-dependency. Q7R down-regulated the production of MDA and increased the hepatic GSH content and antioxidant enzymes CAT activities. Hepatic morphological analysis was also performed to confirm the biochemical changes. In summary, these results suggested that Q7R could be considered as a potential source of natural antioxidants, and may become a promising candidate for the treatment of liver injury in the future.


1 September 2019 in Life Sciences
Verified
Journal Article
Closed access
CPChen Pan
Chen Pan
HYHongliang Yao
Hongliang Yao
WSWeiwei Su
Weiwei Su
YHYudong He
Yudong He
KCKeling Cheng
Keling Cheng
PLPei-bo Li
Pei-bo Li

1 October 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZCZhen Chen
Zhen Chen
HWHao Wu
Hao Wu
RSRui Shi
Rui Shi
WFWeiyang Fan
Weiyang Fan
JZJiashuo Zhang
Jiashuo Zhang
PLPei-bo Li
Pei-bo Li

21 July 2025 in Pharmacological Research
Verified
Journal Article
Open access
XHXinru Huang
Xinru Huang
HWHao Wu
Hao Wu
XWXiao Wu
Xiao Wu
WSWeiwei Su
Weiwei Su
PLPei-bo Li
Pei-bo Li
The intestinal microflora represents a collection of microorganisms residing in the gastrointestinal tract. Alterations in the composition of the intestinal microflora may disrupt the stability of the intestinal ecosystem and adversely affect the health of the host. Previously, growing studies have demonstrated that dietary interventions have the potential to reshape the intestinal microflora and thereby promote host health. Naringenin and naringin are natural dietary flavonoids, which possess a wide range of biological activities, including anti-inflammatory, antioxidant, anticancer, hypoglycemic activities, and the ability to improve lipid metabolism. Studies indicate that the intestinal microflora can metabolize naringenin and naringin into several phenolic and aromatic ring-fission catabolites, and consequently exerting unique physiological activities. In turn, naringenin and naringin were found to impact on the composition and metabolites of intestinal microflora. This review will summarize existing studies on naringenin/naringin therapeutic effects and the role of intestinal microflora in them, and discuss their potential to improve host health as natural agents.

18 July 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ZCZhen Chen
Zhen Chen
HWHao Wu
Hao Wu
WFWeiyang Fan
Weiyang Fan
JZJiashuo Zhang
Jiashuo Zhang
YYYue Yao
Yue Yao
PLPei-bo Li
Pei-bo Li
Extracellular vesicles (EVs)-mediated epithelium-macrophage crosstalk has been proved to maintain lung homeostasis in cigarette smoke-induced lung diseases such as chronic obstructive pulmonary disease (COPD). In our previous study, we found that EVs derived from cigarette smoke extract (CSE) treated BEAS-2B promoted M1 macrophage polarization, which probably accelerated the development of inflammatory responses. Naringenin has been proved to suppress M1 macrophage polarization, but whether naringenin regulates macrophage polarization mediated by EVs has not been reported. In this study, we firstly found that EVs derived from naringenin and CSE co-treated BEAS-2B significantly inhibited the expression of CD86 and CD80 and the secretion of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β, inducible nitric oxide synthase (iNOS), and IL-12 in macrophage induced by EVs derived from CSE-treated BEAS-2B. Further research revealed that naringenin downregulated BEAS-2B-derived EVs miR-21-3p which targeted phosphatase and tensin homolog deleted on chromosome ten/protein kinase B (PTEN/AKT) cascade in macrophages and then suppressed M1 macrophage polarization. Subsequent proteomics suggested that naringenin decreased BEAS-2B-derived EVs poly ADP-ribose polymerase (PARP)1 expression thereby suppressing M1 macrophage polarization probably. Our study provides novel pharmacological references for the mechanism of naringenin in the treatment of cigarette smoke-induced lung inflammatory diseases.